Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 17;10(8):e29840.
doi: 10.1016/j.heliyon.2024.e29840. eCollection 2024 Apr 30.

Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review

Siqi Ni  1 , Qi Liang  1 , Xingyu Jiang  1 , Yinping Ge  2 , Yali Jiang  2 , Lingxiang Liu  1
Affiliations
Review

Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review

Siqi Ni et al. Heliyon. .

Abstract

The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of lung cancer. Given the limited clinical benefits of immunotherapy in patients with non-small cell lung cancer (NSCLC), various predictors have been shown to significantly influence prognosis. However, no single predictor is adequate to forecast patients' survival benefit. Therefore, it's imperative to develop a prognostic model that integrates multiple predictors. This model would be instrumental in identifying patients who might benefit from ICIs. Retrospective analysis and small case series have demonstrated the potential role of these models in prognostic prediction, though further prospective investigation is required to evaluate more rigorously their application in these contexts. This article presents and summarizes the latest research advancements on immunotherapy prognostic models for NSCLC from multiple omics perspectives and discuss emerging strategies being developed to enhance the domain.

Keywords: Immune checkpoint inhibitors; Non-small cell lung cancer; Prognostic model.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Prognostic models for immunotherapy in NSCLC by Figdraw (www.figdraw.com). (A) Clinical-based prognostic models. (B) Pathomics-based models. (C) Genomics-based models. (D) Radiomics-based models.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. - PubMed
    1. Abd El‐Salam M.A., Smith C.E.P., Pan C.X. Insights on recent innovations in bladder cancer immunotherapy. Cancer Cytopathology. 2022;130(9):667–683. - PubMed
    1. Wang D.-R., Wu X.-L., Sun Y.-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Targeted Ther. 2022;7(1):331. - PMC - PubMed
    1. Samstein R.M., Lee C.-H., Shoushtari A.N., Hellmann M.D., Shen R., Janjigian Y.Y., Barron D.A., Zehir A., Jordan E.J., Omuro A., Kaley T.J., Kendall S.M., Motzer R.J., Hakimi A.A., Voss M.H., Russo P., Rosenberg J., Iyer G., Bochner B.H., Bajorin D.F., Al-Ahmadie H.A., Chaft J.E., Rudin C.M., Riely G.J., Baxi S., Ho A.L., Wong R.J., Pfister D.G., Wolchok J.D., Barker C.A., Gutin P.H., Brennan C.W., Tabar V., Mellinghoff I.K., DeAngelis L.M., Ariyan C.E., Lee N., Tap W.D., Gounder M.M., D'Angelo S.P., Saltz L., Stadler Z.K., Scher H.I., Baselga J., Razavi P., Klebanoff C.A., Yaeger R., Segal N.H., Ku G.Y., DeMatteo R.P., Ladanyi M., Rizvi N.A., Berger M.F., Riaz N., Solit D.B., Chan T.A., Morris L.G.T. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019;51(2):202–206. - PMC - PubMed
    1. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., Patnaik A., Aggarwal C., Gubens M., Horn L., Carcereny E., Ahn M.-J., Felip E., Lee J.-S., Hellmann M.D., Hamid O., Goldman J.W., Soria J.-C., Dolled-Filhart M., Rutledge R.Z., Zhang J., Lunceford J.K., Rangwala R., Lubiniecki G.M., Roach C., Emancipator K., Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015;372(21):2018–2028. - PubMed

LinkOut - more resources